Artal Group’s ImmunityBio IBRX Stock Holding History

Artal Group’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-225,000	Closed	-$1.01M	–	124
2017 Q4	$1.01M	Hold	225,000	–	–	0.02%	113
2017 Q3	$1.23M	Hold	225,000	–	–	0.02%	103
2017 Q2	$1.71M	Hold	225,000	–	–	0.03%	97
2017 Q1	$799K	Hold	225,000	–	–	0.02%	91
2016 Q4	$1.29M	Hold	225,000	–	–	0.03%	83
2016 Q3	$1.75M	Hold	225,000	–	–	0.03%	87
2016 Q2	$1.4M	Hold	225,000	–	–	0.03%	66
2016 Q1	$1.85M	Hold	225,000	–	–	0.04%	55
2015 Q4	$3.9M	Buy	225,000 +50,000	+29%	+$742K	0.07%	67
2015 Q3	$2.01M	Buy	+175,000	New	+$3.82M	0.04%	68

Other funds holding IBRX

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VIA

Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artal Group's IBRX Position: Q1 2018 in Review

Artal Group sold out of ImmunityBio (IBRX) in Q1 2018, closing a stake of 225,000 shares — an estimated $1.01M sold.

Artal Group first reported a position in IBRX in Q3 2015 and held it in 10 quarters. The position peaked at $3.9M in Q4 2015. 62 funds tracked by Wall St. Rank hold IBRX as of Q1 2018.

Artal Group reported no remaining ImmunityBio position as of Q1 2018 after selling out during the quarter.
Artal Group sold 225,000 ImmunityBio shares in Q1 2018, an estimated $1.01M.
Artal Group first reported a position in ImmunityBio in Q3 2015 and held it in 10 quarters.
Artal Group's ImmunityBio position peaked at $3.9M in Q4 2015.
62 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2018.

Based on Artal Group's 13F filing for Q1 2018, filed 10 May 2018.